Navigation Links
Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:2/25/2009

- MDV3100 Consistently Demonstrates Anti-Tumor Activity Across Doses and Endpoints in both Chemotherapy Naive and Post-Chemotherapy Patients -

- Data To Be Presented at ASCO's 2009 Genitourinary Cancers Symposium -

- Medivation to Host Conference Call and Webcast Presentation with Dr. Howard Scher Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, Feb. 25 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new efficacy and safety data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (CRPC) patients. The new efficacy data cover all 114 patients who have been followed for 12 weeks or longer, and show that MDV3100 consistently demonstrated encouraging anti-tumor activity across dose levels and endpoints.

"The data thus far suggest a favorable benefit/risk ratio for MDV3100 in treating castration-resistant prostate cancer patients," said Howard Scher, M.D., principal investigator of the trial and chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center. "These men have a limited life expectancy, and currently their only approved treatment option is chemotherapy. Given these encouraging results and the large unmet medical need for men with castration-resistant prostate cancer, I am enthusiastic about working with Medivation to advance MDV3100 into Phase 3 clinical development this year."

All patients had progressive disease upon enrollment and were heavily pretreated, with 77 percent having failed at least two lines of prior hormonal therapy and 43 percent having also failed one or more chemotherapy regimens. Efficacy endpoints in the study included circulating tumor
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Medivation Presents New Data on Dimebons Novel Mechanism of Action
2. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
3. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
4. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
5. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
6. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
7. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
8. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
9. Medivation Announces Participation in Upcoming Conferences
10. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
11. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 21, 2014   ... Commercial Officer zu KLOX    ... Chief Financial Officer bestellt    KLOX ... seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    ... "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... (PRWEB) November 19, 2014 The science ... lives was shared with more than 200 primary students ... students from the University of Otago Physics Department and ... The Otago students, members of the university’s OSA/SPIE Student ... in early September, giving children from small, rural schools ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 The ... public policy research organization representing leading California academic ... and PwC US today released a ... life sciences industry growth. The trend shows a ... 2015 California Biomedical Industry Report indicates ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 BlueInGreen, ... Ozone Solutions, LLC (Pinnacle), and PCI, Inc., leading ... that they have been selected to provide a ... Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... patented HyDOZ® gas dissolution technology, Pinnacle ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4
... Israel, January 16, Rosetta Genomics Ltd. (Nasdaq: ... data relating to the company,s,colorectal cancer screening ... a simple blood draw, and is expected ... and collaborators have identified microRNA biomarkers in,serum, ...
... of two new large scale,trials show that the ... effective against uncomplicated malaria in a way which,is ... it,also protects patients against new infections for at ... very well tolerated with no significant,side effects. , ...
... The H9N2 strain of influenza commonly infects poultry ... FluForecast® software, has studied the Replikin Count® annually ... H5N1. Cyclic increases and decreases appear to ... increases occurring in advance of, and being greater ...
Cached Biology Technology:Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic; Identified Candidate MicroRNA Biomarkers in Serum 2Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic; Identified Candidate MicroRNA Biomarkers in Serum 3Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic; Identified Candidate MicroRNA Biomarkers in Serum 4Malaria: New Treatment is Upcoming 2Malaria: New Treatment is Upcoming 3Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1 2Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1 3
(Date:11/4/2014)... about the way our bodies are assembled during early ... they are supposed to become a nerve or a ... correct place and alignment? Researchers at the University of ... a new study, UM researchers describe the signaling systems ... at the head-trunk region. Their discovery may have important ...
(Date:11/4/2014)... England , November 4, 2014 ... and vertical market growth   Fuel3D , ... has closed a funding round totaling $6.4 million (£4 million). ... million) funding secured earlier this year and paves the way ... in 2015. The funding round was led by ...
(Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology , ... announced that the latest version of its fingerprint ... Ongoing MINEX evaluation organized by NIST. ... algorithms using the INCITS 378 fingerprint standard template ... in public tenders in the United ...
Breaking Biology News(10 mins):The inside story: How the brain and skull stay together 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
... is growing scientific concern that corals could retreat from equatorial ... team of international marine researchers warned today. Working on ... episode of global warming, the period between the last two ... of a sharp decline in coral diversity near the equator. ...
... obesity occurs, eating fatty and sugary foods causes chemical changes ... feel similar to going through drug withdrawal, according to a ... of Montreal,s Faculty of Medicine and its affiliated CRCHUM Hospital ... many ways comparable to our own, we discovered that the ...
... Joanna Lambert, professor in the UTSA Department of Anthropology, ... for the Advancement of Science (AAAS) for the outstanding ... feeding biology at evolutionary and ecological scales. Lambert ... scientifically or socially distinguished efforts to advance science or ...
Cached Biology News:Scary news for corals -- from the Ice Age 2Could ending your fatty food habit cause withdrawal symptoms and depression? 2UTSA anthropologist honored for contributions researching primates in Africa 2
Mouse monoclonal [X223] to Lamin B1 + B2 - Nuclear Envelope Marker ( Abpromise for all tested applications). entrezGeneID: 4001 SwissProtID: P20700...
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
Biology Products: